BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33232371)

  • 1. Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles.
    Tegally H; Kensler KH; Mungloo-Dilmohamud Z; Ghoorah AW; Rebbeck TR; Baichoo S
    PLoS One; 2020; 15(11):e0242780. PubMed ID: 33232371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
    Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
    Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of druggable cancer driver genes amplified across TCGA datasets.
    Chen Y; McGee J; Chen X; Doman TN; Gong X; Zhang Y; Hamm N; Ma X; Higgs RE; Bhagwat SV; Buchanan S; Peng SB; Staschke KA; Yadav V; Yue Y; Kouros-Mehr H
    PLoS One; 2014; 9(5):e98293. PubMed ID: 24874471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators.
    Simeone I; Ceccarelli M
    J Transl Med; 2023 Jan; 21(1):55. PubMed ID: 36717859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes.
    Youn A; Kim KI; Rabadan R; Tycko B; Shen Y; Wang S
    BMC Med Genomics; 2018 Nov; 11(1):98. PubMed ID: 30400878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel ratio-metric features enable the identification of new driver genes across cancer types.
    Sudhakar M; Rengaswamy R; Raman K
    Sci Rep; 2022 Jan; 12(1):5. PubMed ID: 34997044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Method for Identifying the Potential Cancer Driver Genes Based on Molecular Data Integration.
    Zhang W; Wang SL
    Biochem Genet; 2020 Feb; 58(1):16-39. PubMed ID: 31115714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
    Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
    Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events.
    Ashouri A; Sayin VI; Van den Eynden J; Singh SX; Papagiannakopoulos T; Larsson E
    Nat Commun; 2016 Oct; 7():13197. PubMed ID: 28959951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
    Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
    BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer assessment of mutational landscape in intrinsically disordered hotspots reveals potential driver genes.
    Zou H; Pan T; Gao Y; Chen R; Li S; Guo J; Tian Z; Xu G; Xu J; Ma Y; Li Y
    Nucleic Acids Res; 2022 May; 50(9):e49. PubMed ID: 35061901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LNDriver: identifying driver genes by integrating mutation and expression data based on gene-gene interaction network.
    Wei PJ; Zhang D; Xia J; Zheng CH
    BMC Bioinformatics; 2016 Dec; 17(Suppl 17):467. PubMed ID: 28155630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational landscape of RNA-binding proteins in human cancers.
    Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
    RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovering potential cancer driver genes by an integrated network-based approach.
    Shi K; Gao L; Wang B
    Mol Biosyst; 2016 Aug; 12(9):2921-31. PubMed ID: 27426053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of coding and non-coding mutational hotspots in cancer genomes.
    Piraino SW; Furney SJ
    BMC Genomics; 2017 Jan; 18(1):17. PubMed ID: 28056774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pan-cancer analysis of gain-of-functional mutations to identify the common oncogenic signatures in multiple cancers.
    Wee Y; Liu Y; Bhyan SB; Lu J; Zhao M
    Gene; 2019 May; 697():57-66. PubMed ID: 30796966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysis.
    Merid SK; Goranskaya D; Alexeyenko A
    BMC Bioinformatics; 2014 Sep; 15(1):308. PubMed ID: 25236784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer.
    D Antonio M; Weghorn D; D Antonio-Chronowska A; Coulet F; Olson KM; DeBoever C; Drees F; Arias A; Alakus H; Richardson AL; Schwab RB; Farley EK; Sunyaev SR; Frazer KA
    Nat Commun; 2017 Sep; 8(1):436. PubMed ID: 28874753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.